ONAPGO, a subcutaneous infusion device, treats motor fluctuations in advanced Parkinson's disease and launches in the U.S. in 2025. Supernus Pharmaceuticals has announced the FDA approval of ONAPGO, ...
Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl]) for ...
A new Supernus Pharmaceuticals medical device that continuously administers an old Parkinson’s disease drug is now FDA approved, giving patients another way to manage the motor control symptoms that ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced Parkinson's disease, Supernus Pharmaceuticals announced on Tuesday. The ...
(RTTNews) - Supernus Pharmaceuticals, Inc. (SUPN), a biopharmaceutical company, announced on Tuesday the FDA approval of ONAPGO or apomorphine hydrochloride for the treatment of motor fluctuations in ...
Supernus Pharmaceuticals, Inc. ( SUPN) Bank of America Global Healthcare Conference 2026 May 12, 2026 6:40 PM EDT ...
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) gained in the premarket on Thursday after Piper Sandler upgraded the neurology-focused drug developer to Overweight from Neutral, citing a promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results